Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995-2005.
about
Vaccination strategies in patients with solid organ transplant: evidences and future perspectivesReview of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project dataVaricella zoster vaccines and their implications for development of HSV vaccinesTrends in varicella mortality in the United States: Data from vital statistics and the national surveillance system.Simultaneous cocirculation of both European varicella-zoster virus genotypes (E1 and E2) in Mexico city.Fatal varicella due to the vaccine-strain varicella-zoster virus.Successes and challenges in varicella vaccineVaricella zoster disease of the central nervous system: epidemiological, clinical, and laboratory features 10 years after the introduction of the varicella vaccineVaricella zoster virus DNA at inoculation sites and in saliva after Zostavax immunizationEvidence-based clinical guidelines for immigrants and refugees.Novel genetic variation identified at fixed loci in ORF62 of the Oka varicella vaccine and in a case of vaccine-associated herpes zosterPharmacovigilance in children: detecting adverse drug reactions in routine electronic healthcare records. A systematic review.Neurovirulence of varicella and the live attenuated varicella vaccine virus.A Toddler With Rash, Encephalopathy, and Hemolytic Anemia.Recombinant varicella-zoster virus vaccines as platforms for expression of foreign antigens.Pathogenesis and current approaches to control of varicella-zoster virus infections.Deep sequencing of viral genomes provides insight into the evolution and pathogenesis of varicella zoster virus and its vaccine in humans.Varicella zoster virus-induced pain and post-herpetic neuralgia in the human host and in rodent animal models.Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004-2009.Molecular studies of the Oka varicella vaccine.Clinical and molecular aspects of the live attenuated Oka varicella vaccine.Adverse events following immunization: real causality and myths.Severe varicella in persons vaccinated with varicella vaccine (breakthrough varicella): a systematic literature reviewGenotype analysis of ORF 62 identifies varicella-zoster virus infections caused by a vaccine strain in children.Perspectives on vaccines against varicella-zoster virus infections.Novel polyvalent live vaccine against varicella-zoster and mumps virus infections.Transmission of varicella vaccine virus, JapanVaricella Virus Vaccination in the United States.A spot of bother: Why varicella vaccine programs matter.
P2860
Q26739160-565037AD-F8BD-4C78-BED6-C22B20910B0AQ26863614-0A46821F-CD98-4C54-BE8A-00107005DE84Q28280820-221FE15D-5735-4999-97BE-04A8F36BA4DFQ30899562-FE5738B6-15A9-44B1-804D-DE07980995D8Q33827257-9152EB3F-A418-400D-9CCD-3AEF4AA25173Q34271522-FCF5866F-D851-4E16-B9F6-4540B99559A1Q34416710-CB414CCD-8D54-4CE3-9F19-36E023256068Q34763836-0C5E72F9-7992-459E-BAF2-F909292471CCQ34988283-EDFCDFD7-9E60-44FF-9E5D-07EF00EE12CBQ35201293-DD3EDB07-3811-4C1F-8B91-1233B8A39A2BQ35942988-0A9B79C9-3D5C-47DF-A3C8-0C4712DAE647Q36125536-259AAB59-CB4E-4160-A796-9986DE6EDDADQ36164992-BC54E86E-2E94-436B-9543-B4B59CAD9152Q36377382-F22972F5-31B8-4FE4-BEA6-2A8DD38476D4Q36969576-5D2DC897-D27E-4C5B-8792-6A5F9DEEDF2FQ37263293-6DEB02D1-FA00-4505-B84F-0E18CAD31181Q37532874-A0B9789B-B6A1-44DC-B6CD-80FD743BF14EQ37625435-1FDA470A-64A2-4336-937A-B8CBD90B3DF1Q37908267-9E695042-23A6-454B-B45F-79808FA4B4BAQ37932527-B26DE2DB-40DF-44D5-8E5E-0092AEBAFA0EQ38200971-01CDF368-FF13-45EF-90E3-7BB614DFFDB1Q38778111-896899EF-48CB-4C2C-BEC2-E0E8C7CAE770Q39170004-E99B0B55-0262-4345-B92F-51B1C2EE6117Q40330700-7B0F9ABE-D6CF-443A-9519-7165D0E79CF2Q40363716-762F7701-F0E4-4FC4-BA8F-0D66CDA230A2Q42279811-AFA821AC-915A-438D-B615-15AC8EB96604Q42789434-465FB7DF-10B8-42AE-868C-92EF0725D5E9Q45324301-B61E6D55-D539-44A1-8E41-E93E91B75CC2Q55054018-A25940D9-0E52-4F4C-AE16-EA497CC97E1E
P2860
Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995-2005.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Safety of varicella vaccine af ...... t reporting system, 1995-2005.
@en
Safety of varicella vaccine af ...... t reporting system, 1995-2005.
@nl
type
label
Safety of varicella vaccine af ...... t reporting system, 1995-2005.
@en
Safety of varicella vaccine af ...... t reporting system, 1995-2005.
@nl
prefLabel
Safety of varicella vaccine af ...... t reporting system, 1995-2005.
@en
Safety of varicella vaccine af ...... t reporting system, 1995-2005.
@nl
P2093
P2860
P356
P1476
Safety of varicella vaccine af ...... t reporting system, 1995-2005.
@en
P2093
D Scott Schmid
Hector S Izurieta
Jane F Seward
Kimp Walton
Penina Haber
Robert P Wise
Sandra S Chaves
P2860
P304
P356
10.1086/522161
P407
P478
197 Suppl 2
P577
2008-03-01T00:00:00Z